FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Comparing Liposomal Bupivacaine and Ropivacaine in Serratus Anterior Plane Block for Thoracoscopic Lobectomy: A Randomized Controlled Trial. PMID 40491528 · Drug Des Devel Ther · 2025 The study is a randomized controlled trial in oncology patients, but it lacks a reported phase, its primary endpoint is a pain score (not time-to-event), and the intervention is a local anesthetic for postoperative pain management, not an anticancer drug intervention for efficacy against the malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Designing a multi-arm, multi-stage platform trial for venous leg ulceration - Venous leg ulcers: management and eradication, the VEIN platform study.: Designing a platform/adaptive trial for venous leg ulcers (VLU) - The VEIN platform. PMID 40487135 · NIHR Open Res · 2025 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Optimizing muscle mass and function in advanced lung cancer patients: randomized, double-blind, placebo-controlled trial protocol using High Eicosapentaenoic acid and PROtein (HEPRO) to modulate epigenetics, reduce toxicity and improve gut microbiota. PMID 40487055 · PeerJ · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Validation and pilot feasibility study of a novel screener to assess diet, lifestyle and mental health in people living with and beyond cancer: Study protocols. PMID 40472046 · PLoS One · 2025 The record is a protocol for a validation and pilot feasibility study, not a formal report of results from a definitive randomized trial. It does not meet the criteria for Phase III/IIIb or Phase II/III, drug intervention, or time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease. PMID 40470513 · Biologics · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Lanadelumab for prevention of attacks of non-histaminergic normal C1 inhibitor angioedema: results from the randomized, double-blind CASPIAN Study and CASPIAN open-label extension. PMID 40469312 · Front Immunol · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| GPT-4 generates accurate and readable patient education materials aligned with current oncological guidelines: A randomized assessment. PMID 40465696 · PLoS One · 2025 This is a randomized trial assessing AI-generated patient education materials for oncological guidelines. While it involves oncology and human subjects, it is not a drug intervention trial, does not report Phase III/IIIb or Phase II/III results, and lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. The study's primary outcomes are readability, accuracy, completeness, and clarity scores. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Anxiolysis for laceration repair in children: study protocol for an open-label multicenter adaptive trial (ALICE). PMID 40465577 · PLoS One · 2025 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models. PMID 40458731 · Front Oncol · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Single-centre, single-blind, randomized, active-controlled phase-3 non-inferiority study to investigate the safety and efficacy of the cardioplegic solution Cardioplexol™. PMID 40458598 · Front Cardiovasc Med · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| 12-Month Outcomes of a Prospective Randomized Trial Investigating Effects of IVIG on Top of rATG Versus rATG Alone in Pre-Sensitized Kidney Transplant Recipients: The INHIBIT Study. PMID 40458542 · Transpl Int · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Immunomodulatory Effect of Vitamin B12 in Pernicious Anemia: A Systematic Review. PMID 40458194 · Oxid Med Cell Longev · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Thalidomide confers therapeutic benefit in beta thalassemia patients by enhancing hemoglobin and hematopoietic gene expression: A non-randomized clinical trial. PMID 40446669 · Blood Cells Mol Dis · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Association of predicted lean body mass and fat mass with prognosis in patients with heart failure preserved ejection fraction. PMID 40446077 · PLoS One · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Genomewide association analysis on green tea chemoprevention of colorectal adenoma: the importance of SLCO1A2 variants. PMID 40433816 · Pharmacogenomics · 2025 The record is a post-hoc pharmacogenetic analysis of the MIRACLE trial. It does not meet key inclusion criteria: the intervention is a dietary supplement (green tea extract), not a conventional drug; the primary endpoint is adenoma recurrence (binary), not a time-to-event; and the analysis is a subgroup/biomarker study, not the primary efficacy report. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Supplementation of multienzyme with acidifier alleviates the antinutritional effects of a high soybean meal diet for nursery pigs. PMID 40433456 · Front Vet Sci · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Comparison between the safety of the HPV vaccine versus placebo: a systematic review and meta-analysis of randomized clinical trials. PMID 40425051 · J Pediatr (Rio J) · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| CONKO-011/AIO-SUP-0115/ass.: Rivaroxaban Compared to Low Molecular Weight Heparin in Cancer Patients with Acute Venous Thromboembolism. PMID 40418924 · Oncol Res Treat · 2025 Study is a Phase III randomized trial in cancer patients with a drug intervention, but its primary endpoint is patient-reported treatment satisfaction (ACTS), and secondary endpoints include quality of life, safety, and compliance. While overall mortality is listed as a secondary endpoint, it is not presented with time-to-event analysis (e.g., Kaplan-Meier, HR) in the abstract; results focus on patient-reported outcomes and descriptive mortality. Therefore, it lacks a primary or key secondary time-to-event efficacy endpoint as required. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Post hoc exploratory analysis of the effect of foslevodopa/foscarbidopa continuous subcutaneous infusion on nocturia in patients with Parkinson's disease. PMID 40417229 · Clin Park Relat Disord · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of 0.5% Timolol Maleate versus 0.05% Clobetasol Propionate in Treating Superficial Infantile Hemangioma: A Pilot Randomized Controlled Trial. PMID 40406337 · J Indian Assoc Pediatr Surg · 2025 The study is a randomized, placebo-controlled trial in oncology (benign vascular tumor/hemangioma), but it is a Phase II (pilot) study, not Phase III/IIIb or Phase II/III. The primary outcomes are descriptive measures (area reduction, visual analog scale scores) at fixed timepoints, not time-to-event endpoints like OS, PFS, or DFS, and no Kaplan-Meier curves or hazard ratios are reported. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The efficacy and effectiveness of enterovirus A71 vaccines against hand, foot, and mouth disease: A systematic review and meta-analysis. PMID 40402938 · PLoS One · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Effect of Helicobacter pylori eradication on remnant stomach neoplasms after curative gastrectomy (HELP-GC): Protocol of a HELP-GC randomized controlled trial. PMID 40388525 · PLoS One · 2025 The record is a protocol for a randomized controlled trial with drug intervention and time-to-event endpoints, but it is not an original formal result report. It lacks Phase III/IIIb or Phase II/III evidence and presents no efficacy data, so it does not meet eligibility criteria for inclusion in the digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness of atezolizumab versus chemotherapy in patients with non-small-cell lung cancer ineligible for platinum-based doublet chemotherapy. PMID 40385627 · Front Public Health · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Cost-effectiveness analyses of amivantamab plus lazertinib and lazertinib versus osimertinib in non-small cell lung cancer with EGFR mutations. PMID 40385479 · Front Pharmacol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Rivaroxaban Versus Warfarin for the Treatment of Cerebral Venous Thrombosis (RWCVT): A Randomized Controlled Trial in Resource-Limited Setting. PMID 40376280 · Stroke Res Treat · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Treatment mechanism and research progress of bevacizumab for glioblastoma. PMID 40371151 · Am J Cancer Res · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of behavioral activation in reducing fear of cancer recurrence in non-small cell lung cancer patients: a randomized controlled trial. PMID 40371137 · Am J Cancer Res · 2025 The study is a randomized trial in oncology patients, but it fails three key eligibility criteria: it is not a definitive phase (Phase III/IIIb or II/III), its primary endpoint is not a time-to-event efficacy outcome, and the intervention is non-drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The effects of saffron supplementation on inflammatory factors and clinical outcomes in sepsis patients admitted to the intensive care unit (ICU): Study protocol for a double-blind randomized controlled clinical trial. PMID 40365184 · Avicenna J Phytomed · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Reduced Port Surgery for Colorectal Cancer. PMID 40355129 · Asian J Endosc Surg · 2025 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Personalized targeted glioblastoma therapies by ex vivo drug screening: Study protocol of the Advanced brain Tumor TheRApy Clinical Trial (ATTRACT). PMID 40351832 · Neurooncol Adv · 2025 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| [Novel treatment strategies for polycythemia vera: focus on ropeginterferon alfa-2b]. PMID 40350277 · Rinsho Ketsueki · 2025 The record is a review article discussing clinical trial results, not an original primary research report. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges. PMID 40329596 · Technol Cancer Res Treat · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Applying the Principal Stratum Strategy in Equivalence Trials: A Case Study. PMID 40326608 · Pharm Stat · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Resistance exercise combined with protein supplementation for skeletal muscle mass in people with pancreatic cancer undergoing neoadjuvant chemotherapy: Study protocol for the REBUILD trial. PMID 40315221 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Influence of polyfunctional Tbet+ T cells on specific clinical events in chronic lymphocytic leukaemia. PMID 40313965 · Front Immunol · 2025 The record describes a secondary/biomarker analysis from a Phase III randomized trial. While the trial itself is oncology, human, randomized, and drug-interventional, this specific publication does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier results or hazard ratios for the compared treatment regimens. It focuses on correlating baseline T-cell phenotypes with clinical events in a subset of patients. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Real-world comparison of flumatinib and nilotinib as first-line therapy for patients with chronic phase chronic myeloid leukemia: a multicenter retrospective study. PMID 40309039 · Ther Adv Med Oncol · 2025 The study is a retrospective real-world comparison, not a randomized Phase III/IIIb or Phase II/III trial. It does not report a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with Kaplan-Meier or HR. |
H
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Clinical outcomes of baricitinib in patients with systemic lupus erythematosus: Pooled analysis of SLE-BRAVE-I and SLE-BRAVE-II trials. PMID 40305472 · PLoS One · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| An internet-delivered psychoeducational intervention (Fex-Can 2.0) targeting fertility-related distress and sexual dysfunction in young adults diagnosed with cancer: Study protocol of a randomized controlled trial with an internal pilot phase. PMID 40300010 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates. PMID 40296876 · Bladder Cancer · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ensitrelvir as a novel treatment option for mild-to-moderate COVID-19: a narrative literature review. PMID 40292087 · Ther Adv Infect Dis · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Evaluating Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Influenza: A Sensitivity Analysis Based on Information Theory and Causal Inference. PMID 40290204 · J Glob Infect Dis · 2025 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Prognostic significance of KRAS, NRAS, BRAF, and PIK3CA mutations in stage II/III colorectal cancer: A retrospective study and meta-analysis. PMID 40279317 · PLoS One · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD. PMID 40271423 · J Vitreoretin Dis · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Immunogenicity and safety of a multi-human dose formulation of Biological E's 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14®) administered to 6-8-week-old healthy infants: a phase 3, single-blind, randomized, active-controlled study. PMID 40260247 · Front Immunol · 2025 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Capecitabine metronomic chemotherapy for metastatic colorectal cancer patients reaching NED: A protocol for a prospective, randomized, controlled trial. PMID 40258007 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effectiveness of theory-based breast self-examination intervention for breast cancer prevention among female college teachers in Pakistan: A cluster randomized controlled trial study protocol. PMID 40245100 · PLoS One · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Perception of Lemborexant Effectiveness as Assessed by the Patient Global Impression-Insomnia Questionnaire. PMID 40225286 · Nat Sci Sleep · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials. PMID 40209685 · Dermatology · 2025 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of PD-1/PD-L1 inhibitors as first-line treatment for esophageal squamous cell carcinoma: a systematic review and meta-analysis. PMID 40207226 · Front Immunol · 2025 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Qizhu Yuling prescription in the prevention of postoperative metastasis and recurrence of esophagus cancer: study protocol for a randomized, double-blind, placebo-controlled, multicenter clinical trial. PMID 40206581 · Front Oncol · 2025 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |